Market Overview

Amarin Popped Amid Press Release In Friday's After-Hours Session

Related AMRN
7 Biotech Movers To Watch Today: Prothena, Proteostasis, Global Blood Therapeutics And More
20 Stocks Moving In Wednesday's Pre-Market Session

Amarin Corporation plc (ADR) (NASDAQ: AMRN) shares are trading higher by $0.07 (3.7 percent) at $2.13 in Monday's session. The issue spiked in Friday's after-hours session, following the release of the American Heart Association's CHERRY abstract summaries.

In Friday's session, it finally cleared the horde of sellers that had been keeping a lid on the issue at the $2 area since mid-October. Friday's close of $2.04 (one penny off its high) marked the first time it closed above $2 since October 9, when it ended the session at $2.08.

The issue spiked nearly 22 percent to $2.45 (on 8,000 shares) just before the conclusion of the after-hours session at 8:00 p.m. ET.

On Monday morning, Amarin commented on the new data from a CHERRY study focusing on VascepA capsules, the highly-purified EPA drug therapy that may reduce residual risk in coronary heart disease patients already.

The reaction in Monday's session has been muted. After a flat open, it rallied to $2.19 before falling back to its current level. The rally is taking place on higher than average volume. So far, 1.5 million shares have traded compared to its 20-day average of 1.1 million, with less than four hours remaining in the session.

Editor's note: A previous version of this story did not mention that the abstracts were released on Friday afternoon.

Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.

Do you like this article? Do you have suggestions for improvement? Please email

Posted-In: Premarket outlookTechnicals After-Hours Center Movers Trading Ideas


Related Articles (AMRN)

View Comments and Join the Discussion!